In models of autoimmunity, cancer and infection, activation-induced downregulation of CCR6 releases γδT17 cells from their homeostatic immunosurveillance trafficking circuit through the skin and circulation, which then enhances their CCR2-dependent homing to inflamed tissue. Here, CCR6 is linked to cancer.